Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAmBxV9NwPCJF00tOcDOvIaWVPltHn-LOIupuYkqY93fI#assertion>. }
Showing items 1 to 19 of
19
with 100 items per page.
- MONDO_0005090 type Disease assertion.
- DB01267 type Drug assertion.
- context type Cohort assertion.
- association type ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- MONDO_0005090 label "Manic bipolar affective disorder" assertion.
- DB01267 label "Paliperidone" assertion.
- context label "Children and adolescents (6-17 years)" assertion.
- association label "Paliperidone is FDA-approved for schizophrenia aged 12-17. However, the pharmacologic portfolio, extrapolation from adult studies, and the long track record of the parent drug, risperidone in child/adolescent psychiatric (CAP) population might expand its therapeutic potential. An 8-week open-label study [9] examined paliperidone monotherapy for acute mania, mixed, or hypomanic episode in pediatric patients (n = 15, 6–17 years of age) with bipolar spectrum disorders. At the end of follow-up period, 11 subjects (73%) completed the study; treatment with paliperidone was associated with a 60% response rate (50% decrease in the Young Mania Rating Scale) and 40% remission (YMRS <12)" assertion.
- association subject DB01267 assertion.
- association predicate treats assertion.
- association object MONDO_0005090 assertion.
- association has_population_context context assertion.
- association relation NCIT_C94303 assertion.
- MONDO_0005090 category Disease assertion.
- DB01267 category Drug assertion.
- context category Cohort assertion.
- association category ChemicalToDiseaseOrPhenotypicFeatureAssociation assertion.
- association publications 31096228 assertion.
- association aggregator_knowledge_source knowledge-collaboratory assertion.